论文部分内容阅读
目的探讨不同剂量氯沙坦对肝硬化门静脉高压症大鼠的治疗作用。方法采用复合因素法制作大鼠肝硬化门静脉高压症(PHT)模型,43只雄性Wistar大鼠随机分为5组:正常对照组(n=7)、模型对照组(n=6)、三个治疗组分别给予10mg/(kg.d)、5mg/(kg.d)、2.5mg/(kg.d)高、中、低三种剂量氯沙坦(各组n=10)。结果治疗15d结束后,与模型对照组比较,各治疗组肝静脉压力梯度(HVPG)均有显著下降(P<0.05),但仍高于正常对照组(P<0.05)。治疗组之间比较差别无统计学意义。而高剂量组平均动脉压(MAP)从(94.44±11.23)mmHg下降到(70.81±12.57)mmHg。治疗组均可降低血清透明质酸(HA)的含量(P<0.05)。结论氯沙坦能有效地降低HVPG,减轻肝纤维化而用于门静脉高压症的治疗。中、低剂量具有与高剂量类似的治疗效果,且对全身血流动力学影响小。
Objective To investigate the therapeutic effects of losartan on rats with cirrhosis and portal hypertension. Methods Forty-three male Wistar rats were randomly divided into five groups: normal control group (n = 7), model control group (n = 6), three The treatment group were given losartan (10mg / (kg · d), 5mg / (kg · d), 2.5mg / (kg · d) high, medium and low doses respectively. Results After 15 days of treatment, compared with the model control group, the HVPG of each treatment group decreased significantly (P <0.05), but still higher than that of the normal control group (P <0.05). The difference between the treatment group was not statistically significant. However, mean arterial pressure (MAP) in high dose group decreased from (94.44 ± 11.23) mmHg to (70.81 ± 12.57) mmHg. The treatment group can reduce the serum hyaluronic acid (HA) content (P <0.05). Conclusion Losartan can effectively reduce HVPG, reduce liver fibrosis for the treatment of portal hypertension. Medium and low doses have similar therapeutic effects as high doses with little impact on systemic hemodynamics.